TABLE 2.

Main clinical AEs reported by patients and main laboratory AEs detected at any time after the first dose of fixed or nonfixed AS-MQ until the end of follow-up at 28 days^a

AE	No. (%)
	AS-MQ fixed (n = 24)	AS + MQ nonfixed (n = 25)
Gastrointestinal
Anorexia	3 (12.5)	0 (0.0)
Nausea	2 (8.3)	2 (8.0)
Vomiting	2 (8.3)	2 (8.0)
Flatulence	1 (4.2)	1 (4.0)
Abdominal pain	4 (16.7)	2 (8)
Diarrhea	1 (4.2)	1 (4.0)
Constipation	0 (0.0)	2 (8.0)
Respiratory
Nasal congestion	2 (8.3)	0 (0.0)
URTIb	6 (25.0)	3 (12.0)
Cough	2 (8.3)	1 (4.0)
Chest pain	1 (4.2)	0 (0.0)
Palpitations	1 (4.2)	0 (0.0)
Musculoskeletal
Myalgia	1 (4.2)	1 (4.0)
Neck pain	0 (0.0)	1 (4.0)
Pain in extremity	0 (0.0)	2 (8.0)
Central nervous system
Weakness	0 (0.0)	2 (8.0)
Dizziness	0 (0.0)	4 (16.0)
Headache	3 (12.5)	3 (12.0)
Insomnia	4 (16.7)	1 (4.0)
Vertigo	0 (0.0)	1 (4.0)
Skin
Itching	1 (4.2)	2 (8.0)
Rash	1 (4.2)	1 (4.0)
General symptoms
Fever	4 (16.7)	2 (8.0)
Dehydration	0 (0.0)	1 (4.0)
Epistaxis	1 (4.2)	0 (0.0)
Infections/infestations
Abscess	0 (0.0)	1 (4.0)
Hordeolum	1 (4.2)	0 (0.0)
Gut helminths	15 (62.6)	6 (24.0)
Tuberculosis	1 (4.2)	0 (0.0)
Laboratory findings
Anemia	5 (20.8)	2 (8.0)
Eosinophilia	20 (83.3)	21 (84.0)
ALT/AST increased	2 (8.3)	4 (16.0)
Hypoglycemiab	0 (0.0)	1 (4.0)
Microscopic hematuria	3 (12.5)	4 (16.0)
Proteinuria	8 (33.3)	3 (12.0)

^aPatients may have had more than one adverse event.

^bURTI, upper respiratory tract infection.

^cPlasma glucose, ≤66 mg/dl; lower limit of normal for laboratory, 75 mg/dl.